All In Biotech

Drug Trial Radar · NCT04240886

Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds

A Phase 2, Open-Label Study to Evaluate the Safety and Efficacy of APX001 in the Treatment of Patients With Invasive Mold Infections Caused by Aspergillus Species or Rare Molds

Last checked: Nov 20, 2026Latest source record: Sep 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

21

Actual

Start

Jan 4, 2020

Primary completion

Mar 29, 2022

Study completion May 9, 2022

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, multicenter study to evaluate APX001 for the treatment of invasive fungal infections caused by Aspergillus spp. or rare molds (eg, Scedosporium spp., Fusarium spp., and Mucorales fungi).

Conditions

  • Invasive Fungal Infections

Interventions

  • fosmanogepixDrug

    IV and oral fosmanogepix

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Died After the First Dose of Study Drug Through Day 42Time frame: After first dose on Day 1 through Day 42

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

    Duarte, California

  • IP Address : City of Hope Investigational Drug Services (IDS)

    Duarte, California

  • Duke Department of Pharmacy/Investigational Drug Service (IDS)

    Durham, North Carolina

  • Duke Medicine Pavilion

    Durham, North Carolina

  • Duke University Medical Center (Duke South Clinic)

    Durham, North Carolina

  • Duke University Medical Center(Duke Hospital)

    Durham, North Carolina

  • Cliniques Universitaires de Bruxelles Hôpital Erasme - Department of Infectious Diseases

    Brussels, Belgium

  • UZ Leuven - Department of Haematology

    Leuven, Belgium

  • CHU UCL Namur - Mont- Godinne University Hospital - Intensive Care Unit

    Yvoir, Belgium

  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz III

    Mainz, Germany

  • Klinikum Neuperlach, Klinik fur Hamatologie und Onkologie

    München, Bavaria, Germany

  • Pharmacy

    Haifa, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Pharmacy

    Ramat Gan, Israel

  • Sheba Medical Center, Tel Hashomer

    Ramat Gan, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.